理解伴显著核仁的脾B细胞淋巴瘤/白血病:诊断、疾病分类基础及未来方向
世界卫生组织血液淋巴肿瘤分类第5版(WHO-HAEM5)新设伴显著核仁的脾B细胞淋巴瘤/白血病(SBLPN)类别,取消B细胞幼淋巴细胞白血病(B-PLL)诊断并重新概念化毛细胞白血病变异型(HCLv)。本文综述取消B-PLL和HCLv诊断的理由,探讨SBLPN概念,提供诊断实践指导并讨论脾B细胞淋巴瘤分类的未来方向。
要点
- WHO-HAEM5新设SBLPN类别,作为不符合现有分类的实体的临时归类。
- B-PLL诊断已取消,HCLv概念已重新界定。
- 既往诊断为CD5阴性B-PLL和HCLv的病例归入SBLPN类别。
核心结论
- WHO-HAEM5引入SBLPN作为临时归类,以容纳不符合现有分类的脾B细胞淋巴瘤/白血病实体。
- B-PLL诊断已取消,HCLv概念已重新界定,部分既往诊断为CD5阴性B-PLL和HCLv的病例归入SBLPN。
研究设计与样本
- 综述,探讨取消B-PLL和HCLv诊断的理由、SBLPN概念、诊断实践指导及未来分类方向。
主要发现
- B-PLL和HCLv诊断不常见。
- B-PLL与其他惰性淋巴瘤如慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)存在重叠。
- HCLv缺乏一致的细胞形态学、免疫表型和遗传学特征。
- 部分脾边缘区淋巴瘤和脾弥漫性红髓小B细胞淋巴瘤病例若含较多中等或大核仁B细胞,在WHO-HAEM5下也将归类为SBLPN。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 5th edition of the WHO classification of haematolymphoid tumours (WHO-HAEM5) introduced a new category, splenic B-cell lymphoma/leukaemia with prominent nucleoli (SBLPN). The diagnostic entity B-cell prolymphocytic leukaemia (B-PLL) has been discontinued and the category of hairy cell leukaemia variant (HCLv) has been conceptually reframed. B-PLL and HCLv diagnoses were uncommon. Overlap existed between B-PLL and other indolent lymphomas like chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL). HCLv lacked consistent cytomorphological, immunophenotypic and genetic features. To address these issues, the WHO-HAEM5 classification has introduced SBLPN to serve as a temporary holding ground for entities that do not neatly fit into the existing classification. Cases previously classified as CD5-negative B-PLL and HCLv fall under the SBLPN category. Some splenic marginal zone lymphoma and splenic diffuse red pulp small B-cell lymphoma cases with higher number of medium or large nucleolated B cells would also be classified as SBLPN under the WHO-HAEM5. This review explores the rationale for discontinuing B-PLL and HCLv diagnoses. It then examines the concept of SBLPN, offers practical guidance for diagnosis and discusses future directions in classifying splenic B-cell lymphomas.
引用
- Naresh KN. Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions. Br J Haematol. 2024. PMID: 39253895. doi:10.1111/bjh.19754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。